JointHealth™ express   November 22, 2023

Let BC PharmaCare hear "Your Voice" on nirmatrelvir-ritonavir (Paxlovid™) for the treatment of COVID-19

Nirmatrelvir-ritonavir (Paxlovid™) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about Paxlovid™ for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19.

You can give input if you are a B.C. resident and have COVID-19, a caregiver to someone with COVID-19, or if your group represents people who live with COVID-19.

If you would like our help in providing your input, you can email your comments to Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Friday, December 15 so that we may submit the questionnaire in time for the deadline.

The submission deadline is December 19, 2023. Patients and caregivers may give their input directly through the link below.

Please click on information sheet link below to learn more about Paxlovid™ and the questionnaire link below to let BC PharmaCare hear Your Voice:
  • To view the information sheet for Paxlovid™ for the treatment of COVID-19: click here
  • To complete the Questionnaire as a patient, caregiver, or patient group representative: click here